Dissociated incretin response to oral glucose at 1 year after restrictive vs. malabsorptive bariatric surgery

Diabetes, Obesity and Metabolism

Volumn 11, Issue 11, 2009, Pages 1027-1033

  Guldstrand, M ^a   Ahren B ^b   Naslund E ^a   Holst, J J ^c   Adamson, U ^a  

^a DANDERYD HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

GIP; GLP 1; Glucagon like peptide 1; Glucose tolerance; Glucose dependent insulinotropic polypeptide; Insulin; Obesity; Weight reduction

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GASTROPLASTY; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HORMONE RELEASE; HORMONE RESPONSE; HUMAN; INSULIN BLOOD LEVEL; INTERMETHOD COMPARISON; JEJUNOILEAL BYPASS; OBESITY; POSTOPERATIVE PERIOD; SURGICAL TECHNIQUE; THERAPY EFFECT; WEIGHT REDUCTION;

ADULT; BARIATRIC SURGERY; FEMALE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INCRETINS; OBESITY, MORBID; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 70350192133     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2009.01089.x     Document Type: Article

References (46)

1. Sjostrom L. Surgical interventions as a strategy for treatment of obesity. Endocrine 2000, 13:213-230.
2. Buchwald H, Avidor Y, Braundwald E. Bariatric surgery: a systematic review and meta-analysis. J Am Med Assoc 2004, 292:1724-1737.
3. Dixon JB, O'brien PE, Playfair J. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. J Am Med Assoc 2008, 299:316-323.
4. Depaula AL, Macedo AL, Rassi N. Laparoscopic treatment of type 2 diabetes mellitus for patients with a body mass index less than 35. Surg Endosc 2008, 22:706-716.
5. Pontiroli AE, Pizzocri P, Librenti MC. Laparoscopic adjustable gastric banding for the treatment of morbid (grade 3) obesity and its metabolic complications: a three-year study. J Clin Endocrinol Metab 2002, 87:3555-3561.
6. Vetter ML, Cardillo S, Rickels MR, Iqbal N. Narrative review: effect of bariatric surgery on type 2 diabetes mellitus. Ann Intern Med 2009, 150:94-103.
7. Mingrone G, Degaetano A, Greco AV. Reversibility of insulin resistance in obese diabetic patients: role of plasma lipids. Diabetologia 1995, 40:599-605.
8. Guldstrand M, Ahren B, Adamson U. Improved β-cell function after standardized weight reduction in severely obese subjects. Am J Physiol 2003, 284:E557-E565.
9. Rubino F. Bariatric surgery: effects on glucose homeostasis. Curr Opin Clin Nutr Metab Care 2006, 9:497-507.
10. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132:2131-2157.
11. Bose M, Olivan B, Teixeira J, Pi-Sunyer FX, Lafferere. Do incretins play a role in the remission of type 2 diabetes after gastric bypass surgery: what are the evidence?. Obes Surg 2009, 19:217-229.
12. Mingrone G. Role of the incretin system in the remission of type 2 diabetes following bariatric surgery. Nutr Metab Cardiovasc Dis 2008, 18:574-579.
13. Laferrere B, Teixeira J, McGinty J. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab 2008, 3:2479-2487.
14. Naslund E, Gryback P, Backman L. Distal small bowel hormones: correlation with fasting antroduodenal motility and gastric emptying. Dig Dis Sci 1998, 43:945-952.
15. Korner J, Bessler M, Inabnet W, Taveras C, Holst JJ. Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not by adjustable gastric banding. Surg Obes Relat Dis 2007, 3:597-601.
16. Folli F, Pontiroli AE, Schwesinger WH. Metabolic aspects of bariatric surgery. Med Clin North Am 2007, 91:393-414.
17. Shak JR, Roper J, Perez-Perez GI. The effect of laparoscopic gastric banding surgery on plasma levels of appetite-control, insulinotropic, and digestive hormones. Obese Surg 2008, 18:1089-1096.
18. Whitson BA, Leslie DB, Kellogg TA. Entero-endocrine changes after gastric bypass in diabetic and non-diabetic patients: a preliminary study. J Surg Res 2007, 141:31-39.
19. Sjostrom CD, Peltonen M, Wedel H, Sjostrom L. Differentiated long-term effects of intentional weight loss on diabetes and hypertension. Hypertension 2000, 36:20-25.
20. Sjostrom L. Surgical intervention as a strategy for treatment of obesity. Endocrine 2000, 13:213-230.
21. Backman L. The rate of weight loss after intestinal bypass operations for obesity. Acta Chir Scand 1975, 141:424-430.
22. Mason EE. Vertical banded gastroplasty for obesity. Arch Surg 1982, 117:701-706.
23. Payne J, DeWind L. Surgical treatment of obesity. Am J Surg 1969, 118:141-147.
24. Backman L, Hallberg D. Small-intestinal length. An intraoperative study in obesity. Acta Chir Scand 1974, 140:57-63.
25. Krarup T, Madsbad S, Moody AJ. Diminished immunoreactive gastric inhibitory polypeptide response to a meal in newly diagnosed type 1 (insulin dependent) diabetics. J Clin Endocrinol Metab 1983, 56:1306-1312.
26. Deacon CF, Nauck MA, Meier J, Hücking K, Holst JJ. Degradation of endogenous and exogenous gastric inhibitory polypeptide (GIP) in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 2000, l85:3575-3581.
27. Orskov C, Rabenhoj L, Kofod H. Production and secretion of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 1994, 43:535-539.
28. Mari A, Pacini G, Murphy E, Ludvik B, Nolan JJ. A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care 2001, 25:539-548.
29. Mari A, Pacini G, Brazzale AR, Ahren B. Comparative evaluation of simple insulin sensitivity methods based on the oral glucose tolerance test. Diabetologia 2005, 48:748-751.
30. Holst JJ, Sorensen TIA, Nyboe Andersen A. Plasma enteroglucagon after jejuno-ileal bypass with 3:1 and 1:3 jejunoileal ratio. Scand J Gastroenterol 1979, 14:205-207.
31. Naslund E, Melin I, Gryback P. Reduced food intake after jejunoileal bypass: a possible association with prolonged gastric emptying and altered gut hormone patterns. Am J Clin Nutr 1997, 66:26-32.
32. Naslund E, Backman L, Granstrom L, Stockeld D. Seven year results of vertical banded gastroplasty for morbid obesity. Eur J Surg 1997, 163:281-286.
33. Marsk R, Jonas E, Gartzios H, Stockeld D, Granstrom L, Fieddman J. High revision rates after laparoscopic vertical banded gastroplasty. Surg Obes Relat Dis 2009, 5:94-98.
34. Verdich C, Toubro S, Buemann B. The role of postprandial releases of insulin and incretin hormones in meal-induced satiety-effect of obesity and weight reduction . Int J Obes Relat Metab Disord 2001, 25:1206-1214.
35. Jones IR, Owens Dr, Luzio SD, Hayes TM. Obesity is associated with increased post-prandial GIP levels which are not reduced by dietary restriction and weight loss. Diabetes Metab 1989, 15:11-22.
36. Holst JJ. On the physiology of GIP and GLP-1. Horm Metab Res 2004, 36:747-754.
37. Rubino F, Forgione A, Cummings DE. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg 2006, 244:741-749.
38. Strader AD, Vahl TP, Jandacek RJ, Wood SC, D'Alessio DA, Seeley RJ. Weight loss through ileal transposition is accompanied by increased ileal hormone secretion and synthesis in rats. Am J Physiol 2005, 288:E447-E453.
39. Miyawaki K, Yamada Y, Ban N. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nature Med 2002, 8:738-742.
40. Gault VA, McClean PL, Cassidy RS, Irwin N, Flatt PR. Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets. Diabetologia 2007, 50:1752-1762.
41. Irwin N, McClean PL, O'harte FP, Gault VA, Harriott P, Flatt PR. Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (pro3) GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice. Diabetologia 2007, 50:1532-1540.
42. McClean PL, Irwin N, Cassidy RS, Holst JJ, Gault VA, Flatt PR. GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet. Am J Physiol 2007, 293:E1746-E1755.
43. Naslund E, Backman L, Holst JJ, Theodorsson E, Hellström PM. Importance of small bowel peptides for the improved glucose metabolism 20 years after jejunoileal bypass for obesity. Obes Surg 1998, 8:253-260.
44. Vahl TP, Tauchi M, Durler TS. Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. Endocrinology 2007, 148:4965-4973.
45. Kim DH, D'alessio DA, Woods SC, Seeley RJ. The effects of GLP-1 infusion in the hepatic portal region on food intake. Regul Pept 2009, 155:110-114.
46. Ballantyne GH. Peptide YY (1-36) and peptide YY (3-36). Part II. Changes after gastrointestinal surgery and bariatric surgery. Obes Surg 2006, 16:795-803.